149 related articles for article (PubMed ID: 27015113)
1. Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study.
Kim SC; Schneeweiss S; Liu J; Karlson EW; Katz JN; Feldman S; Solomon DH
Arthritis Rheumatol; 2016 Sep; 68(9):2106-13. PubMed ID: 27015113
[TBL] [Abstract][Full Text] [Related]
2. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
Kim SC; Solomon DH; Liu J; Franklin JM; Glynn RJ; Schneeweiss S
Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
Kim G; Barner JC; Rascati K; Richards K
J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
[TBL] [Abstract][Full Text] [Related]
4. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
5. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
Jin Y; Desai RJ; Liu J; Choi NK; Kim SC
Arthritis Res Ther; 2017 Jul; 19(1):159. PubMed ID: 28679392
[TBL] [Abstract][Full Text] [Related]
7. Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection.
Burton MJ; Curtis JR; Yang S; Chen L; Singh JA; Mikuls TR; Winthrop KL; Baddley JW
J Rheumatol; 2017 May; 44(5):565-570. PubMed ID: 28250142
[TBL] [Abstract][Full Text] [Related]
8. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
9. Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014.
Sparks JA; Krumme AA; Shrank WH; Matlin OS; Brill G; Pezalla EJ; Choudhry NK; Solomon DH
Arthritis Rheumatol; 2016 Jul; 68(7):1588-95. PubMed ID: 26866506
[TBL] [Abstract][Full Text] [Related]
10. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic lupus erythematosus receiving immunosuppressive drugs.
Feldman CH; Liu J; Feldman S; Solomon DH; Kim SC
Lupus; 2017 Jun; 26(7):682-689. PubMed ID: 27799438
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.
Setoguchi S; Solomon DH; Weinblatt ME; Katz JN; Avorn J; Glynn RJ; Cook EF; Carney G; Schneeweiss S
Arthritis Rheum; 2006 Sep; 54(9):2757-64. PubMed ID: 16947774
[TBL] [Abstract][Full Text] [Related]
12. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.
Winthrop KL; Baddley JW; Chen L; Liu L; Grijalva CG; Delzell E; Beukelman T; Patkar NM; Xie F; Saag KG; Herrinton LJ; Solomon DH; Lewis JD; Curtis JR
JAMA; 2013 Mar; 309(9):887-95. PubMed ID: 23462785
[TBL] [Abstract][Full Text] [Related]
13. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Solomon DH; Massarotti E; Garg R; Liu J; Canning C; Schneeweiss S
JAMA; 2011 Jun; 305(24):2525-31. PubMed ID: 21693740
[TBL] [Abstract][Full Text] [Related]
14. Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983-2009.
Kim SC; Yelin E; Tonner C; Solomon DH
Arthritis Care Res (Hoboken); 2013 Sep; 65(9):1529-33. PubMed ID: 23463543
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of nonbiologic versus biologic disease-modifying antirheumatic drugs for rheumatoid arthritis.
Dewitt EM; Li Y; Curtis JR; Glick HA; Greenberg JD; Anstrom KJ; Kremer JM; Reed G; Schulman KA; Reed SD
J Rheumatol; 2013 Feb; 40(2):127-36. PubMed ID: 23322461
[TBL] [Abstract][Full Text] [Related]
16. Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study.
Burton MJ; Curtis JR; Yang S; Chen L; Singh JA; Mikuls TR; Winthrop KL; Baddley JW
Arthritis Res Ther; 2015 May; 17(1):136. PubMed ID: 26001631
[TBL] [Abstract][Full Text] [Related]
17. Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden.
Wadström H; Frisell T; Sparén P; Askling J;
Ann Rheum Dis; 2016 Jul; 75(7):1272-8. PubMed ID: 26755797
[TBL] [Abstract][Full Text] [Related]
18. Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study.
Desai RJ; Eddings W; Liao KP; Solomon DH; Kim SC
Arthritis Care Res (Hoboken); 2015 Apr; 67(4):457-66. PubMed ID: 25302481
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs.
Zhang HF; Gauthier G; Hiscock R; Curtis JR
Arthritis Res Ther; 2014 Aug; 16(4):420. PubMed ID: 25146329
[TBL] [Abstract][Full Text] [Related]
20. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
